For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Start JEVTANA with prednisone after a docetaxel-containing regimen to
Offer your mCRPC patients MORE1

MORE Survival1

15.1 months (95% CI: 14.1 - 16.3) median overall survival for patients receiving JEVTANA (n=378) vs 12.7 months (95% CI: 11.6 - 13.7) with mitoxantrone (n=377) (P<0.0001). Number of deaths 234 (62%) with JEVTANA vs 279 (74%) with mitoxantrone.

MORE Tumor Response1

JEVTANA delivered a ≥30% (RECIST Criteria) reduction in tumors in 3X more mCRPC patients vs mitoxantrone, an active comparator: 14.4% (29/201) (95% CI: 9.6 - 19.3) vs 4.4% (9/204) (95% CI: 1.6 - 7.2) (P=0.0005).2,3

Recommended Dosing1

JEVTANA 20 mg/m2 every three weeks + oral prednisone 10 mg daily throughout treatment. 25 mg/m2 can be used in select patients. 

JEVTANA is a NCCN designated Category 1 second-line therapy for mCRPC.4

IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are leaving jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue Cancel